Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review

Table 3

Quantitative data for trial outcomes (continuous).

DRV/r versus LPV/r (ARTEMIS)	Mean change, DRV/r	Total, DRV/r	Mean change, LPV/r	Total, LPV/r
Immunologic recovery (192 weeks)	+258 cells/µL	343	+263 cells/µL	346
Immunologic recovery (96 weeks)	+171 cells/µL	343	+188 cells/µL	346
Immunologic recovery (48 weeks)	+137 cells/µL	343	+141 cells/µL	346
DRV/r versus DTG (FLAMINGO)	Mean change, DRV/r	Total, DRV/r	Mean change, DTG	Total, DTG
Immunologic recovery (96 weeks)	+250 cells/µL	245	+260 cells/µL	243
Immunologic recovery (48 weeks)	+210 cells/µL; IQR 110–290	245	+210 cells/µL; IQR 120–350	243
DRV/r versus RAL (ACTG 5257)	Mean change, DRV/r	Total, DRV/r	Mean change, RAL	Total, RAL
Immunologic recovery (96 weeks)	+256 cells/µL	601	+288 cells/µL	603
DRV/r versus ATV/r (ACTG 5257)	Mean change, DRV/r	Total, DRV/r	Mean change, ATV/r	Total, ATV/r
Immunologic recovery (96 weeks)	+256 cells/µL	601	+280 cells/µL	605

IQR, interquartile range; DRV/r, ritonavir-boosted darunavir-based regimen; DTG, dolutegravir-based regimen; LPV/r, ritonavir-boosted lopinavir-based regimen; ATV/r, ritonavir-boosted atazanavir-based regimen; RAL, raltegravir-based regimen.